Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Protein S, a natural anticoagulant controls Pancreatic Ductal Adenocarcinoma by mediating both antitumor and antithrombotic effects

Award Number: R01CA304610
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/10/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2031

Group Awards By:

View Award Description

Protein S, a natural anticoagulant controls Pancreatic Ductal Adenocarcinoma by mediating both antitumor and antithrombotic effects - Project Summary Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, with a 5-year survival rate below 13%. Beyond its aggressive biology, PDAC carries the highest incidence of venous thromboembolism (VTE) of any cancer, which further shortens survival and complicates therapy. This dual burden—rapid tumor progression and thrombosis—represents an urgent, unmet clinical challenge that current therapies fail to address in combination. Protein S (PS), a natural anticoagulant encoded by PROS1, uniquely integrates anticoagulant and immunemodulatory functions by binding both activated Factor IX (FIXa) and TAM family receptors (Tyro3, Axl, Mer). Our preliminary studies reveal that PS supplementation suppresses PDAC tumor growth, alleviates hypoxia, and reduces thrombosis in preclinical models—an unprecedented dual action not observed with standard anticoagulants. We hypothesize that PS deficiency drives PDAC progression and hypercoagulability, and that physiologic restoration of PS can simultaneously inhibit tumor growth and thrombosis through integrated coagulation and immune regulatory pathways. • Aim 1: Characterize plasma PS levels and PS-regulated transcriptomic signatures across PDAC cohorts to establish PS as a clinically actionable biomarker. • Aim 2: Evaluate the therapeutic efficacy of PS alone and in combination with gemcitabine in orthotopic, humanized, and organoid PDAC models to concurrently reduce tumor progression and VTE. • Aim 3: Dissect the mechanistic contribution of TAM receptor signaling versus FIXa binding in mediating PS’s antitumor effects using pharmacologic, genetic, and mutant PS approaches. Successful completion of this project will (1) define PS as a prognostic biomarker and therapeutic target, (2) establish a first-in-class, dual-action strategy that integrates thrombosis prevention with tumor control, and (3) provide mechanistic clarity to guide future ligand-specific TAM-targeted therapies. By advancing an endogenous anticoagulant with immune-regulatory capacity, this proposal offers a transformative, clinically actionable framework to address the two principal drivers of PDAC mortality—tumor progression and thrombosis. To rigorously evaluate the dual role of Protein S in regulating both thrombosis and tumor progression, we will use both orthotopic and humanized mouse models of PDAC. These in vivo models are essential because they recapitulate the complex tumor microenvironment, systemic coagulation dynamics, and tumor-stroma interactions that cannot be adequately modeled in cell culture or in vitro systems alone.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $621,353 )
2026	2026	LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER NEW ORLEANS	433 BOLIVAR ST RM 619	NEW ORLEANS	LA	70112	ORLEANS	USA	Cancer Treatment Research	000	1	7/10/2026	NEW	$621,353
														Subtotal = $621,353

Grand Total All Awards = $621,353

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Protein S, a natural anticoagulant controls Pancreatic Ductal Adenocarcinoma by mediating both antitumor and antithrombotic effects

Award Number: R01CA304610

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/10/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer